Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Processa Pharmaceuticals Inc (PCSA)

Processa Pharmaceuticals Inc (PCSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS GlobeNewswire - Wed Jul 29, 6:30AM CDT

Acquisition brings into Processa’s pipeline Vidya’s lead asset, VT-7208, a next-generation, CNS-penetrant, once-daily, oral potentially best-in-class Bruton’s tyrosine kinase inhibitor (BTKi) designed...

PCSA : 2.14 (-0.47%)
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Mon Jan 12, 8:15AM CST

VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today...

PCSA : 2.14 (-0.47%)
Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ACCESS Newswire - Fri Jan 9, 3:00AM CST

ORLANDO, FLORIDA / ACCESS Newswire / January 9, 2026 / RedChip Companies will air interviews with Alliance Entertainment Holding Corp. (Nasdaq:AENT) and Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) on...

AENT : 5.64 (+0.36%)
PCSA : 2.14 (-0.47%)
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study GlobeNewswire - Mon Jan 5, 8:15AM CST

Interim safety and efficacy data to be reported in Q1 VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company...

PCSA : 2.14 (-0.47%)
Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ACCESS Newswire - Fri Dec 26, 2025

ORLANDO, FL / ACCESS Newswire / December 26, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip...

PCSA : 2.14 (-0.47%)
SXTP : 1.0920 (-3.36%)
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer GlobeNewswire - Wed Dec 17, 2025

Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track to conduct...

PCSA : 2.14 (-0.47%)
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025 GlobeNewswire - Wed Nov 5, 2025

VERO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative...

PCSA : 2.14 (-0.47%)
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies GlobeNewswire - Thu Aug 7, 2025

VERO BEACH, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for cancer...

PCSA : 2.14 (-0.47%)
Processa Pharmaceuticals and BullFrog AI Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ACCESS Newswire - Fri Jul 18, 2025

ORLANDO, FLORIDA / ACCESS Newswire / July 18, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) and BullFrog AI, Inc. (Nasdaq:BFRG) on the RedChip Small Stocks,...

PCSA : 2.14 (-0.47%)
BFRG : 0.5948 (+4.35%)
Processa Pharmaceuticals Provides Portfolio and Business Update GlobeNewswire - Tue Jul 1, 2025

PCSA : 2.14 (-0.47%)

Barchart Exclusives

1 Trade to Make as the Pro Farmer Crop Tour Wraps Up Barchart - 5 minutes ago
December soybean meal futures present a buying opportunity on more price strength. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.